Loading...
Header Logo
Keywords
Last Name
Institution

Professor Shyam Sundar

Title[no position]
Institution[no institution name]
Address[no address]
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Singh N, Sundar S. Integrating genomics and proteomics permits identification of immunodominant antigens associated with drug resistance in human visceral leishmaniasis in India. Exp Parasitol. 2017 May; 176:30-45. PMID: 28263760.
      View in: PubMed
    2. Singh N, Sundar S. Inflammatory chemokines and their receptors in human visceral leishmaniasis: Gene expression profile in peripheral blood, splenic cellular sources and their impact on trafficking of inflammatory cells. Mol Immunol. 2017 05; 85:111-119. PMID: 28222329.
      View in: PubMed
    3. Singh OP, Hasker E, Boelaert M, Sundar S. Elimination of visceral leishmaniasis on the Indian subcontinent. Lancet Infect Dis. 2016 Dec; 16(12):e304-e309. PMID: 27692643.
      View in: PubMed
    4. Singh N, Kumar R, Engwerda C, Sacks D, Nylen S, Sundar S. Tumor necrosis factor alpha neutralization has no direct effect on parasite burden, but causes impaired IFN-? production by spleen cells from human visceral leishmaniasis patients. Cytokine. 2016 09; 85:184-90. PMID: 27372917.
      View in: PubMed
    5. Singh OP, Singh B, Chakravarty J, Sundar S. Current challenges in treatment options for visceral leishmaniasis in India: a public health perspective. Infect Dis Poverty. 2016 Mar 08; 5:19. PMID: 26951132.
      View in: PubMed
    6. Cameron MM, Acosta-Serrano A, Bern C, Boelaert M, den Boer M, Burza S, Chapman LA, Chaskopoulou A, Coleman M, Courtenay O, Croft S, Das P, Dilger E, Foster G, Garlapati R, Haines L, Harris A, Hemingway J, Hollingsworth TD, Jervis S, Medley G, Miles M, Paine M, Picado A, Poché R, Ready P, Rogers M, Rowland M, Sundar S, de Vlas SJ, Weetman D. Understanding the transmission dynamics of Leishmania donovani to provide robust evidence for interventions to eliminate visceral leishmaniasis in Bihar, India. Parasit Vectors. 2016 Jan 27; 9:25. PMID: 26812963.
      View in: PubMed
    7. Sudarshan M, Singh T, Singh B, Chakravarty J, Sundar S. Suppression of host PTEN gene expression for Leishmania donovani survival in Indian visceral leishmaniasis. Microbes Infect. 2016 05; 18(5):369-72. PMID: 26774334.
      View in: PubMed
    8. Chakravarty J, Sundar S, Chourasia A, Singh PN, Kurle S, Tripathy SP, Chaturbhuj DN, Rai M, Agarwal AK, Mishra RN, Paranjape RS. Outcome of patients on second line antiretroviral therapy under programmatic condition in India. BMC Infect Dis. 2015 Nov 14; 15:517. PMID: 26572102.
      View in: PubMed
    9. Pandey RK, Sharma D, Bhatt TK, Sundar S, Prajapati VK. Developing imidazole analogues as potential inhibitor for Leishmania donovani trypanothione reductase: virtual screening, molecular docking, dynamics and ADMET approach. J Biomol Struct Dyn. 2015; 33(12):2541-53. PMID: 26305585.
      View in: PubMed
    10. Das S, Shah P, Tandon R, Yadav NK, Sahasrabuddhe AA, Sundar S, Siddiqi MI, Dube A. Over-Expression of Cysteine Leucine Rich Protein Is Related to SAG Resistance in Clinical Isolates of Leishmania donovani. PLoS Negl Trop Dis. 2015 Aug; 9(8):e0003992. PMID: 26295340.
      View in: PubMed
    11. Mukherjee B, Paul J, Mukherjee S, Mukhopadhyay R, Das S, Naskar K, Sundar S, Dujardin JC, Saha B, Roy S. Antimony-Resistant Leishmania donovani Exploits miR-466i To Deactivate Host MyD88 for Regulating IL-10/IL-12 Levels during Early Hours of Infection. J Immunol. 2015 Sep 15; 195(6):2731-42. PMID: 26283478.
      View in: PubMed
    12. Sundar S. Visceral leishmaniasis. Trop Parasitol. 2015 Jul-Dec; 5(2):83-5. PMID: 26629448.
      View in: PubMed
    13. Baharia RK, Tandon R, Sharma T, Suthar MK, Das S, Siddiqi MI, Saxena JK, Sundar S, Dube A. Correction: Recombinant NAD-dependent SIR-2 protein of Leishmania donovani: immunobiochemical characterization as a potential vaccine against visceral leishmaniasis. PLoS Negl Trop Dis. 2015 Apr; 9(4):e0003742. PMID: 25901962.
      View in: PubMed
    14. Picado A, Ostyn B, Rijal S, Sundar S, Singh SP, Chappuis F, Das ML, Khanal B, Gidwani K, Hasker E, Dujardin JC, Vanlerberghe V, Menten J, Coosemans M, Boelaert M. Long-lasting insecticidal nets to prevent visceral leishmaniasis in the Indian subcontinent; methodological lessons learned from a cluster randomised controlled trial. PLoS Negl Trop Dis. 2015 Apr; 9(4):e0003597. PMID: 25856238.
      View in: PubMed
    15. Dayakar A, Chandrasekaran S, Veronica J, Sundar S, Maurya R. In vitro and in vivo evaluation of anti-leishmanial and immunomodulatory activity of Neem leaf extract in Leishmania donovani infection. Exp Parasitol. 2015 Jun; 153:45-54. PMID: 25747203.
      View in: PubMed
    16. Abass E, Kang C, Martinkovic F, Semião-Santos SJ, Sundar S, Walden P, Piarroux R, El Harith A, Lohoff M, Steinhoff U. Heterogeneity of Leishmania donovani parasites complicates diagnosis of visceral leishmaniasis: comparison of different serological tests in three endemic regions. PLoS One. 2015; 10(3):e0116408. PMID: 25734336.
      View in: PubMed
    17. Perry MR, Prajapati VK, Menten J, Raab A, Feldmann J, Chakraborti D, Sundar S, Fairlamb AH, Boelaert M, Picado A. Arsenic exposure and outcomes of antimonial treatment in visceral leishmaniasis patients in Bihar, India: a retrospective cohort study. PLoS Negl Trop Dis. 2015 Mar; 9(3):e0003518. PMID: 25730310.
      View in: PubMed
    18. Perry M, Wyllie S, Prajapati V, Menten J, Raab A, Feldmann J, Chakraborti D, Sundar S, Boelaert M, Picado A, Fairlamb A. Arsenic, antimony, and Leishmania: has arsenic contamination of drinking water in India led to treatment- resistant kala-azar? Lancet. 2015 Feb 26; 385 Suppl 1:S80. PMID: 26312902.
      View in: PubMed
    19. Sundar S, Singh A, Chakravarty J, Rai M. Efficacy and safety of miltefosine in treatment of post-kala-azar dermal leishmaniasis. ScientificWorldJournal. 2015; 2015:414378. PMID: 25685839.
      View in: PubMed
    20. Singh N, Chatterjee M, Sundar S. The overexpression of genes of thiol metabolism contribute to drug resistance in clinical isolates of visceral leishmaniasis (kala azar) in India. Parasit Vectors. 2014 Dec 17; 7:596. PMID: 25515494.
      View in: PubMed
    21. Sundar S, Singh A, Rai M, Chakravarty J. Single-dose indigenous liposomal amphotericin B in the treatment of Indian visceral leishmaniasis: a phase 2 study. Am J Trop Med Hyg. 2015 Mar; 92(3):513-7. PMID: 25510715.
      View in: PubMed
    22. Sudarshan M, Singh T, Singh AK, Chourasia A, Singh B, Wilson ME, Chakravarty J, Sundar S. Quantitative PCR in epidemiology for early detection of visceral leishmaniasis cases in India. PLoS Negl Trop Dis. 2014 Dec; 8(12):e3366. PMID: 25503103.
      View in: PubMed
    23. Sundar S, Chakravarty J. Investigational drugs for visceral leishmaniasis. Expert Opin Investig Drugs. 2015 Jan; 24(1):43-59. PMID: 25409760.
      View in: PubMed
    24. Sundar S, Chakravarty J. An update on pharmacotherapy for leishmaniasis. Expert Opin Pharmacother. 2015 Feb; 16(2):237-52. PMID: 25346016.
      View in: PubMed
    25. Bhattacharyya T, Ayandeh A, Falconar AK, Sundar S, El-Safi S, Gripenberg MA, Bowes DE, Thunissen C, Singh OP, Kumar R, Ahmed O, Eisa O, Saad A, Silva Pereira S, Boelaert M, Mertens P, Miles MA. IgG1 as a potential biomarker of post-chemotherapeutic relapse in visceral leishmaniasis, and adaptation to a rapid diagnostic test. PLoS Negl Trop Dis. 2014 Oct; 8(10):e3273. PMID: 25340782.
      View in: PubMed
    26. Kumar D, Tiwary P, Chakravarty J, Sundar S. Association of interleukin-18 gene polymorphism with susceptibility to visceral leishmaniasis in endemic area of Bihar, an Indian population. ScientificWorldJournal. 2014; 2014:852104. PMID: 25405235.
      View in: PubMed
    27. Kumar R, Singh N, Gautam S, Singh OP, Gidwani K, Rai M, Sacks D, Sundar S, Nylén S. Leishmania specific CD4 T cells release IFN? that limits parasite replication in patients with visceral leishmaniasis. PLoS Negl Trop Dis. 2014 Oct; 8(10):e3198. PMID: 25275531.
      View in: PubMed
    28. Chakravarty J, Tiwary NK, Prasad SR, Shukla S, Tiwari A, Mishra RN, Sundar S. Determinants of survival in adult HIV patients on antiretroviral therapy in Eastern Uttar Pradesh: a prospective study. Indian J Med Res. 2014 Oct; 140(4):491-500. PMID: 25488442.
      View in: PubMed
    29. Jaiswal AK, Khare P, Joshi S, Kushawaha PK, Sundar S, Dube A. Th1 stimulatory proteins of Leishmania donovani: comparative cellular and protective responses of rTriose phosphate isomerase, rProtein disulfide isomerase and rElongation factor-2 in combination with rHSP70 against visceral leishmaniasis. PLoS One. 2014; 9(9):e108556. PMID: 25268700.
      View in: PubMed
    30. Bag AK, Saha S, Sundar S, Saha B, Chakrabarti A, Mandal C. Comparative proteomics and glycoproteomics of plasma proteins in Indian visceral leishmaniasis. Proteome Sci. 2014; 12(1):48. PMID: 25276097.
      View in: PubMed
    31. Sundar S, Pandey K, Thakur CP, Jha TK, Das VN, Verma N, Lal CS, Verma D, Alam S, Das P. Efficacy and safety of amphotericin B emulsion versus liposomal formulation in Indian patients with visceral leishmaniasis: a randomized, open-label study. PLoS Negl Trop Dis. 2014 Sep; 8(9):e3169. PMID: 25233346.
      View in: PubMed
    32. Mukherjee S, Mukherjee B, Mukhopadhyay R, Naskar K, Sundar S, Dujardin JC, Roy S. Imipramine exploits histone deacetylase 11 to increase the IL-12/IL-10 ratio in macrophages infected with antimony-resistant Leishmania donovani and clears organ parasites in experimental infection. J Immunol. 2014 Oct 15; 193(8):4083-94. PMID: 25217162.
      View in: PubMed
    33. Mudavath SL, Talat M, Rai M, Srivastava ON, Sundar S. Characterization and evaluation of amine-modified graphene amphotericin B for the treatment of visceral leishmaniasis: in vivo and in vitro studies. Drug Des Devel Ther. 2014; 8:1235-47. PMID: 25214767.
      View in: PubMed
    34. Malaviya P, Hasker E, Picado A, Mishra M, Van Geertruyden JP, Das ML, Boelaert M, Sundar S. Exposure to Phlebotomus argentipes (Diptera, Psychodidae, Phlebotominae) sand flies in rural areas of Bihar, India: the role of housing conditions. PLoS One. 2014; 9(9):e106771. PMID: 25184542.
      View in: PubMed
    35. Malaviya P, Picado A, Hasker E, Ostyn B, Kansal S, Singh RP, Shankar R, Boelaert M, Sundar S. Health & Demographic Surveillance System profile: the Muzaffarpur-TMRC Health and Demographic Surveillance System. Int J Epidemiol. 2014 Oct; 43(5):1450-7. PMID: 25186307.
      View in: PubMed
    36. Guha R, Das S, Ghosh J, Sundar S, Dujardin JC, Roy S. Antimony resistant Leishmania donovani but not sensitive ones drives greater frequency of potent T-regulatory cells upon interaction with human PBMCs: role of IL-10 and TGF-ß in early immune response. PLoS Negl Trop Dis. 2014 Jul; 8(7):e2995. PMID: 25032977.
      View in: PubMed
    37. Singh OP, Sundar S. Immunotherapy and targeted therapies in treatment of visceral leishmaniasis: current status and future prospects. Front Immunol. 2014; 5:296. PMID: 25183962.
      View in: PubMed
    38. Ostyn B, Hasker E, Dorlo TP, Rijal S, Sundar S, Dujardin JC, Boelaert M. Failure of miltefosine treatment for visceral leishmaniasis in children and men in South-East Asia. PLoS One. 2014; 9(6):e100220. PMID: 24941345.
      View in: PubMed
    39. Meena LP, Pandey SK, Rai M, Bharti A, Chakravarty J, Sundar S. Study the drug adherence and possible factor influencing drug adherence in HIV/AIDS patients in north eastern part of India. J Educ Health Promot. 2014; 3:31. PMID: 25013824.
      View in: PubMed
    40. Sundar S, Singh A, Singh OP. Strategies to overcome antileishmanial drugs unresponsiveness. J Trop Med. 2014; 2014:646932. PMID: 24876851.
      View in: PubMed
    41. Stauch A, Duerr HP, Picado A, Ostyn B, Sundar S, Rijal S, Boelaert M, Dujardin JC, Eichner M. Model-based investigations of different vector-related intervention strategies to eliminate visceral leishmaniasis on the Indian subcontinent. PLoS Negl Trop Dis. 2014 Apr; 8(4):e2810. PMID: 24762676.
      View in: PubMed
    42. Sudarshan M, Sundar S. Parasite load estimation by qPCR differentiates between asymptomatic and symptomatic infection in Indian visceral leishmaniasis. Diagn Microbiol Infect Dis. 2014 Sep; 80(1):40-2. PMID: 25023070.
      View in: PubMed
    43. Singh OP, Hasker E, Sacks D, Boelaert M, Sundar S. Asymptomatic Leishmania infection: a new challenge for Leishmania control. Clin Infect Dis. 2014 May; 58(10):1424-9. PMID: 24585564.
      View in: PubMed
    44. Bhattacharyya T, Bowes DE, El-Safi S, Sundar S, Falconar AK, Singh OP, Kumar R, Ahmed O, Boelaert M, Miles MA. Significantly lower anti-Leishmania IgG responses in Sudanese versus Indian visceral leishmaniasis. PLoS Negl Trop Dis. 2014 Feb; 8(2):e2675. PMID: 24587456.
      View in: PubMed
    45. Bhandari V, Sundar S, Dujardin JC, Salotra P. Elucidation of cellular mechanisms involved in experimental paromomycin resistance in Leishmania donovani. Antimicrob Agents Chemother. 2014 May; 58(5):2580-5. PMID: 24550335.
      View in: PubMed
    46. Kumar A, Misra P, Sisodia B, Shasany AK, Sundar S, Dube A. Mass spectrometry-based proteomic analysis of Leishmania donovani soluble proteins in Indian clinical isolate. Pathog Dis. 2014 Feb; 70(1):84-7. PMID: 24115687.
      View in: PubMed
    47. Singh OP, Sundar S. Whole blood assay and visceral leishmaniasis: Challenges and promises. Immunobiology. 2014 Apr; 219(4):323-8. PMID: 24571797.
      View in: PubMed
    48. Picado A, Ostyn B, Singh SP, Uranw S, Hasker E, Rijal S, Sundar S, Boelaert M, Chappuis F. Risk factors for visceral leishmaniasis and asymptomatic Leishmania donovani infection in India and Nepal. PLoS One. 2014; 9(1):e87641. PMID: 24498159.
      View in: PubMed
    49. Gupta R, Kumar V, Kushawaha PK, Tripathi CP, Joshi S, Sahasrabuddhe AA, Mitra K, Sundar S, Siddiqi MI, Dube A. Characterization of glycolytic enzymes--rAldolase and rEnolase of Leishmania donovani, identified as Th1 stimulatory proteins, for their immunogenicity and immunoprophylactic efficacies against experimental visceral leishmaniasis. PLoS One. 2014; 9(1):e86073. PMID: 24475071.
      View in: PubMed
    50. Hasker E, Malaviya P, Gidwani K, Picado A, Ostyn B, Kansal S, Singh RP, Singh OP, Chourasia A, Kumar Singh A, Shankar R, Wilson ME, Khanal B, Rijal S, Boelaert M, Sundar S. Strong association between serological status and probability of progression to clinical visceral leishmaniasis in prospective cohort studies in India and Nepal. PLoS Negl Trop Dis. 2014; 8(1):e2657. PMID: 24466361.
      View in: PubMed
    51. Manandhar KD, Yadav TP, Prajapati VK, Basukala O, Aganja RP, Dude A, Shrivastav ON, Sundar S. Nanonization increases the antileishmanial efficacy of amphotericin B: an ex vivo approach. Adv Exp Med Biol. 2014; 808:77-91. PMID: 24595612.
      View in: PubMed
    52. Khare P, Jaiswal AK, Tripathi CD, Joshi S, Sundar S, Dube A. Efficacy of Leishmania donovani trypanothione reductase, identified as a potent Th1 stimulatory protein, for its immunogenicity and prophylactic potential against experimental visceral leishmaniasis. Parasitol Res. 2014 Mar; 113(3):851-62. PMID: 24370734.
      View in: PubMed
    53. Das S, Shah P, Baharia RK, Tandon R, Khare P, Sundar S, Sahasrabuddhe AA, Siddiqi MI, Dube A. Over-expression of 60s ribosomal L23a is associated with cellular proliferation in SAG resistant clinical isolates of Leishmania donovani. PLoS Negl Trop Dis. 2013; 7(12):e2527. PMID: 24340105.
      View in: PubMed
    54. Mondal D, Alvar J, Hasnain MG, Hossain MS, Ghosh D, Huda MM, Nabi SG, Sundar S, Matlashewski G, Arana B. Efficacy and safety of single-dose liposomal amphotericin B for visceral leishmaniasis in a rural public hospital in Bangladesh: a feasibility study. Lancet Glob Health. 2014 Jan; 2(1):e51-7. PMID: 25104636.
      View in: PubMed
    55. van den Bogaart E, Schoone GJ, England P, Faber D, Orrling KM, Dujardin JC, Sundar S, Schallig HD, Adams ER. Simple colorimetric trypanothione reductase-based assay for high-throughput screening of drugs against Leishmania intracellular amastigotes. Antimicrob Agents Chemother. 2014; 58(1):527-35. PMID: 24189262.
      View in: PubMed
    56. Kumar D, Khanal B, Tiwary P, Mudavath SL, Tiwary NK, Singh R, Koirala K, Boelaert M, Rijal S, Sundar S. Comparative evaluation of blood and serum samples in rapid immunochromatographic tests for visceral leishmaniasis. J Clin Microbiol. 2013 Dec; 51(12):3955-9. PMID: 24048530.
      View in: PubMed
    57. Rai S. Role of efflux pumps and intracellular thiols in natural antimony resistant isolates of Leishmania donovani. PLoS One. 2013; 8(9):e74862. PMID: 24069359.
      View in: PubMed
    58. Prajapati VK, Sharma S, Rai M, Ostyn B, Salotra P, Vanaerschot M, Dujardin JC, Sundar S. In vitro susceptibility of Leishmania donovani to miltefosine in Indian visceral leishmaniasis. Am J Trop Med Hyg. 2013 Oct; 89(4):750-4. PMID: 23980130.
      View in: PubMed
    59. Das M, Saudagar P, Sundar S, Dubey VK. Miltefosine-unresponsive Leishmania donovani has a greater ability than miltefosine-responsive L. donovani to resist reactive oxygen species. FEBS J. 2013 Oct; 280(19):4807-15. PMID: 23890327.
      View in: PubMed
    60. Hazra S, Ghosh S, Das Sarma M, Sharma S, Das M, Saudagar P, Prajapati VK, Dubey VK, Sundar S, Hazra B. Evaluation of a diospyrin derivative as antileishmanial agent and potential modulator of ornithine decarboxylase of Leishmania donovani. Exp Parasitol. 2013 Oct; 135(2):407-13. PMID: 23973194.
      View in: PubMed
    61. Gautam S, Kumar R, Singh N, Singh AK, Rai M, Sacks D, Sundar S, Nylén S. CD8 T cell exhaustion in human visceral leishmaniasis. J Infect Dis. 2014 Jan 15; 209(2):290-9. PMID: 23922369.
      View in: PubMed
    62. Alvar J, Croft SL, Kaye P, Khamesipour A, Sundar S, Reed SG. Case study for a vaccine against leishmaniasis. Vaccine. 2013 Apr 18; 31 Suppl 2:B244-9. PMID: 23598489.
      View in: PubMed
    63. Tiwary P, Kumar D, Mishra M, Singh RP, Rai M, Sundar S. Seasonal variation in the prevalence of sand flies infected with Leishmania donovani. PLoS One. 2013; 8(4):e61370. PMID: 23585896.
      View in: PubMed
    64. Goel R, Rai M, Chakravarty J, Meena LP, Tiwary NK, Sundar S, Bharti A. Clinical profile and response to first-line ARV in HIV patients from Eastern UP and Bihar: a retrospective study. J Assoc Physicians India. 2013 Apr; 61(4):239-43. PMID: 24482962.
      View in: PubMed
    65. Malaviya P, Ravinetto R, Sundar S. Ethical research is grounded in quality data: a clinical data management workshop in Varanasi. Indian J Med Ethics. 2013 Apr-Jun; 10(2):132. PMID: 23697499.
      View in: PubMed
    66. Srivastava P, Gidwani K, Picado A, Van der Auwera G, Tiwary P, Ostyn B, Dujardin JC, Boelaert M, Sundar S. Molecular and serological markers of Leishmania donovani infection in healthy individuals from endemic areas of Bihar, India. Trop Med Int Health. 2013 May; 18(5):548-54. PMID: 23464581.
      View in: PubMed
    67. Ostyn B, Malaviya P, Hasker E, Uranw S, Singh RP, Rijal S, Sundar S, Dujardin JC, Boelaert M. Retrospective Quarterly Cohort Monitoring for patients with Visceral Leishmaniasis in the Indian subcontinent: outcomes of a pilot project. Trop Med Int Health. 2013 Jun; 18(6):725-33. PMID: 23464638.
      View in: PubMed
    68. Guha R, Das S, Ghosh J, Naskar K, Mandala A, Sundar S, Dujardin JC, Roy S. Heterologous priming-boosting with DNA and vaccinia virus expressing kinetoplastid membrane protein-11 induces potent cellular immune response and confers protection against infection with antimony resistant and sensitive strains of Leishmania (Leishmania) donovani. Vaccine. 2013 Apr 08; 31(15):1905-15. PMID: 23499564.
      View in: PubMed
    69. Chandrasekaran S, Dayakar A, Veronica J, Sundar S, Maurya R. An in vitro study of apoptotic like death in Leishmania donovani promastigotes by withanolides. Parasitol Int. 2013 Jun; 62(3):253-61. PMID: 23416156.
      View in: PubMed
    70. Hasker E, Kansal S, Malaviya P, Gidwani K, Picado A, Singh RP, Chourasia A, Singh AK, Shankar R, Menten J, Wilson ME, Wilson ME, Boelaert M, Sundar S. Latent infection with Leishmania donovani in highly endemic villages in Bihar, India. PLoS Negl Trop Dis. 2013; 7(2):e2053. PMID: 23459501.
      View in: PubMed
    71. Singh N, Chikara S, Sundar S. SOLiD™ sequencing of genomes of clinical isolates of Leishmania donovani from India confirm leptomonas co-infection and raise some key questions. PLoS One. 2013; 8(2):e55738. PMID: 23418454.
      View in: PubMed
    72. Sundar S, Singh A. What steps can be taken to counter the increasing failure of miltefosine to treat visceral leishmaniasis? Expert Rev Anti Infect Ther. 2013 Feb; 11(2):117-9. PMID: 23409817.
      View in: PubMed
    73. Mukherjee B, Mukhopadhyay R, Bannerjee B, Chowdhury S, Mukherjee S, Naskar K, Allam US, Chakravortty D, Sundar S, Dujardin JC, Roy S. Antimony-resistant but not antimony-sensitive Leishmania donovani up-regulates host IL-10 to overexpress multidrug-resistant protein 1. Proc Natl Acad Sci U S A. 2013 Feb 12; 110(7):E575-82. PMID: 23341611.
      View in: PubMed
    74. Common variants in the HLA-DRB1-HLA-DQA1 HLA class II region are associated with susceptibility to visceral leishmaniasis. Nat Genet. 2013 Feb; 45(2):208-13. PMID: 23291585.
      View in: PubMed
    75. Mukherjee S, Mukherjee B, Mukhopadhyay R, Naskar K, Sundar S, Dujardin JC, Das AK, Roy S. Imipramine is an orally active drug against both antimony sensitive and resistant Leishmania donovani clinical isolates in experimental infection. PLoS Negl Trop Dis. 2012; 6(12):e1987. PMID: 23301108.
      View in: PubMed
    76. Sundar S, Chakravarty J. Leishmaniasis: an update of current pharmacotherapy. Expert Opin Pharmacother. 2013 Jan; 14(1):53-63. PMID: 23256501.
      View in: PubMed
    77. Stauch A, Duerr HP, Dujardin JC, Vanaerschot M, Sundar S, Eichner M. Treatment of visceral leishmaniasis: model-based analyses on the spread of antimony-resistant L. donovani in Bihar, India. PLoS Negl Trop Dis. 2012; 6(12):e1973. PMID: 23285309.
      View in: PubMed
    78. Kulshrestha A, Bhandari V, Mukhopadhyay R, Ramesh V, Sundar S, Maes L, Dujardin JC, Roy S, Salotra P. Validation of a simple resazurin-based promastigote assay for the routine monitoring of miltefosine susceptibility in clinical isolates of Leishmania donovani. Parasitol Res. 2013 Feb; 112(2):825-8. PMID: 23239091.
      View in: PubMed
    79. Sundar S, Sinha P, Jha TK, Chakravarty J, Rai M, Kumar N, Pandey K, Narain MK, Verma N, Das VN, Das P, Berman J, Arana B. Oral miltefosine for Indian post-kala-azar dermal leishmaniasis: a randomised trial. Trop Med Int Health. 2013 Jan; 18(1):96-100. PMID: 23136856.
      View in: PubMed
    80. Tiwary P, Kumar D, Rai M, Sundar S. PCR-RFLP based method for molecular differentiation of sand fly species Phlebotomus argentipes, Phlebotomus papatasi, and Sergentomyia babu found in India. J Med Entomol. 2012 Nov; 49(6):1515-8. PMID: 23270185.
      View in: PubMed
    81. Singh OP, Stober CB, Singh AK, Blackwell JM, Sundar S. Cytokine responses to novel antigens in an Indian population living in an area endemic for visceral leishmaniasis. PLoS Negl Trop Dis. 2012; 6(10):e1874. PMID: 23150744.
      View in: PubMed
    82. Hasker E, Singh SP, Malaviya P, Picado A, Gidwani K, Singh RP, Menten J, Boelaert M, Sundar S. Visceral leishmaniasis in rural bihar, India. Emerg Infect Dis. 2012 Oct; 18(10):1662-4. PMID: 23017164.
      View in: PubMed
    83. Dayakar A, Chandrasekaran S, Prajapati VK, Veronica J, Sundar S, Maurya R. A rapid method to assess the stage differentiation in Leishmania donovani by flow cytometry. Exp Parasitol. 2012 Dec; 132(4):495-500. PMID: 23022521.
      View in: PubMed
    84. Kushawaha PK, Gupta R, Tripathi CD, Khare P, Jaiswal AK, Sundar S, Dube A. Leishmania donovani triose phosphate isomerase: a potential vaccine target against visceral leishmaniasis. PLoS One. 2012; 7(9):e45766. PMID: 23049855.
      View in: PubMed
    85. Cunningham J, Hasker E, Das P, El Safi S, Goto H, Mondal D, Mbuchi M, Mukhtar M, Rabello A, Rijal S, Sundar S, Wasunna M, Adams E, Menten J, Peeling R, Boelaert M. A global comparative evaluation of commercial immunochromatographic rapid diagnostic tests for visceral leishmaniasis. Clin Infect Dis. 2012 Nov 15; 55(10):1312-9. PMID: 22942208.
      View in: PubMed
    86. Prajapati VK, Mehrotra S, Gautam S, Rai M, Sundar S. In vitro antileishmanial drug susceptibility of clinical isolates from patients with Indian visceral leishmaniasis--status of newly introduced drugs. Am J Trop Med Hyg. 2012 Oct; 87(4):655-7. PMID: 22927497.
      View in: PubMed
    87. Singh RP, Picado A, Alam S, Hasker E, Singh SP, Ostyn B, Chappuis F, Sundar S, Boelaert M. Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India. Trop Med Int Health. 2012 Nov; 17(11):1345-8. PMID: 22882665.
      View in: PubMed
    88. Picado A, Rijal S, Sundar S, Boelaert M. Visceral leishmaniasis treatment in the Indian subcontinent: how to reach the most vulnerable. Expert Rev Anti Infect Ther. 2012 Aug; 10(8):839-41. PMID: 23030320.
      View in: PubMed
    89. Vaish M, Sharma S, Chakravarty J, Sundar S. Evaluation of two novel rapid rKE16 antigen-based tests for diagnosis of visceral leishmaniasis in India. J Clin Microbiol. 2012 Sep; 50(9):3091-2. PMID: 22760038.
      View in: PubMed
    90. Hazra S, Ghosh S, Debnath S, Seville S, Prajapati VK, Wright CW, Sundar S, Hazra B. Antileishmanial activity of cryptolepine analogues and apoptotic effects of 2,7-dibromocryptolepine against Leishmania donovani promastigotes. Parasitol Res. 2012 Jul; 111(1):195-203. PMID: 22297912.
      View in: PubMed
    91. Vanaerschot M, Decuypere S, Downing T, Imamura H, Stark O, De Doncker S, Roy S, Ostyn B, Maes L, Khanal B, Boelaert M, Schönian G, Berriman M, Chappuis F, Dujardin JC, Sundar S, Rijal S. Genetic markers for SSG resistance in Leishmania donovani and SSG treatment failure in visceral leishmaniasis patients of the Indian subcontinent. J Infect Dis. 2012 Sep 01; 206(5):752-5. PMID: 22753945.
      View in: PubMed
    92. Hendrickx S, Inocêncio da Luz RA, Bhandari V, Kuypers K, Shaw CD, Lonchamp J, Salotra P, Carter K, Sundar S, Rijal S, Dujardin JC, Cos P, Maes L. Experimental induction of paromomycin resistance in antimony-resistant strains of L. donovani: outcome dependent on in vitro selection protocol. PLoS Negl Trop Dis. 2012; 6(5):e1664. PMID: 22666513.
      View in: PubMed
    93. Olliaro P, Vaillant MT, Sundar S, Balasegaram M. More efficient ways of assessing treatments for neglected tropical diseases are required: innovative study designs, new endpoints, and markers of effects. PLoS Negl Trop Dis. 2012; 6(5):e1545. PMID: 22666508.
      View in: PubMed
    94. Bhandari V, Kulshrestha A, Deep DK, Stark O, Prajapati VK, Ramesh V, Sundar S, Schonian G, Dujardin JC, Salotra P. Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis. PLoS Negl Trop Dis. 2012; 6(5):e1657. PMID: 22629478.
      View in: PubMed
    95. Sundar S, Singh A, Rai M, Prajapati VK, Singh AK, Ostyn B, Boelaert M, Dujardin JC, Chakravarty J. Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use. Clin Infect Dis. 2012 Aug; 55(4):543-50. PMID: 22573856.
      View in: PubMed
    96. Singh OP, Gidwani K, Kumar R, Nylén S, Jones SL, Boelaert M, Sacks D, Sundar S. Reassessment of immune correlates in human visceral leishmaniasis as defined by cytokine release in whole blood. Clin Vaccine Immunol. 2012 Jun; 19(6):961-6. PMID: 22539471.
      View in: PubMed
    97. Mehrotra S, Fakiola M, Mishra A, Sudarshan M, Tiwary P, Rani DS, Thangaraj K, Rai M, Sundar S, Blackwell JM. Genetic and functional evaluation of the role of DLL1 in susceptibility to visceral leishmaniasis in India. Infect Genet Evol. 2012 Aug; 12(6):1195-201. PMID: 22561395.
      View in: PubMed
    98. Kushawaha PK, Gupta R, Tripathi CD, Sundar S, Dube A. Evaluation of Leishmania donovani protein disulfide isomerase as a potential immunogenic protein/vaccine candidate against visceral Leishmaniasis. PLoS One. 2012; 7(4):e35670. PMID: 22539989.
      View in: PubMed
    99. Kumar S, Kumar D, Chakravarty J, Rai M, Sundar S. Identification and characterization of a novel Leishmania donovani antigen for serodiagnosis of visceral leishmaniasis. Am J Trop Med Hyg. 2012 Apr; 86(4):601-5. PMID: 22492143.
      View in: PubMed
    100. Vaish M, Singh OP, Chakravarty J, Sundar S. rK39 antigen for the diagnosis of visceral leishmaniasis by using human saliva. Am J Trop Med Hyg. 2012 Apr; 86(4):598-600. PMID: 22492142.
      View in: PubMed
    101. Gupta R, Kushawaha PK, Tripathi CD, Sundar S, Dube A. A novel recombinant Leishmania donovani p45, a partial coding region of methionine aminopeptidase, generates protective immunity by inducing a Th1 stimulatory response against experimental visceral leishmaniasis. Int J Parasitol. 2012 May 01; 42(5):429-35. PMID: 22502587.
      View in: PubMed
    102. Sundar S, Chakravarty J. Recent advances in the diagnosis and treatment of kala-azar. Natl Med J India. 2012 Mar-Apr; 25(2):85-9. PMID: 22686715.
      View in: PubMed
    103. Kumari S, Misra P, Tandon R, Samant M, Sundar S, Dube A. Leishmania donovani: immunostimulatory cellular responses of membrane and soluble protein fractions of splenic amastigotes in cured patient and hamsters. PLoS One. 2012; 7(1):e30746. PMID: 22292030.
      View in: PubMed
    104. Verma RK, Prajapati VK, Verma GK, Chakraborty D, Sundar S, Rai M, Dubey VK, Singh MS. Molecular Docking and in Vitro Antileishmanial Evaluation of Chromene-2-thione Analogues. ACS Med Chem Lett. 2012 Mar 08; 3(3):243-7. PMID: 24936236.
      View in: PubMed
    105. Tiwary P, Kumar D, Singh RP, Rai M, Sundar S. Prevalence of sand flies and Leishmania donovani infection in a natural population of female Phlebotomus argentipes in Bihar State, India. Vector Borne Zoonotic Dis. 2012 Jun; 12(6):467-72. PMID: 22217179.
      View in: PubMed
    106. Sundar S, Prajapati VK. Drug targeting to infectious diseases by nanoparticles surface functionalized with special biomolecules. Curr Med Chem. 2012; 19(19):3196-202. PMID: 22612703.
      View in: PubMed
    107. Mehrotra S, Fakiola M, Oommen J, Jamieson SE, Mishra A, Sudarshan M, Tiwary P, Rani DS, Thangaraj K, Rai M, Sundar S, Blackwell JM. Genetic and functional evaluation of the role of CXCR1 and CXCR2 in susceptibility to visceral leishmaniasis in north-east India. BMC Med Genet. 2011 Dec 15; 12:162. PMID: 22171941.
      View in: PubMed
    108. Prajapati VK, Awasthi K, Yadav TP, Rai M, Srivastava ON, Sundar S. An oral formulation of amphotericin B attached to functionalized carbon nanotubes is an effective treatment for experimental visceral leishmaniasis. J Infect Dis. 2012 Jan 15; 205(2):333-6. PMID: 22158723.
      View in: PubMed
    109. Samanta S, Dutta D, Ghoshal A, Mukhopadhyay S, Saha B, Sundar S, Jarmalavicius S, Forgber M, Mandal C, Walden P, Mandal C. Glycosylation of erythrocyte spectrin and its modification in visceral leishmaniasis. PLoS One. 2011; 6(12):e28169. PMID: 22164239.
      View in: PubMed
    110. Picado A, Singh SP, Vanlerberghe V, Uranw S, Ostyn B, Kaur H, Das ML, Sundar S, Rijal S, Tungu P, Boelaert M, Rowland M. Residual activity and integrity of PermaNet® 2.0 after 24 months of household use in a community randomised trial of long lasting insecticidal nets against visceral leishmaniasis in India and Nepal. Trans R Soc Trop Med Hyg. 2012 Mar; 106(3):150-9. PMID: 22137191.
      View in: PubMed
    111. Stauch A, Sarkar RR, Picado A, Ostyn B, Sundar S, Rijal S, Boelaert M, Dujardin JC, Duerr HP. Visceral leishmaniasis in the Indian subcontinent: modelling epidemiology and control. PLoS Negl Trop Dis. 2011 Nov; 5(11):e1405. PMID: 22140589.
      View in: PubMed
    112. Downing T, Stark O, Vanaerschot M, Imamura H, Sanders M, Decuypere S, de Doncker S, Maes I, Rijal S, Sundar S, Dujardin JC, Berriman M, Schönian G. Genome-wide SNP and microsatellite variation illuminate population-level epidemiology in the Leishmania donovani species complex. Infect Genet Evol. 2012 Jan; 12(1):149-59. PMID: 22119748.
      View in: PubMed
    113. Sinha PK, Jha TK, Thakur CP, Nath D, Mukherjee S, Aditya AK, Sundar S. Phase 4 pharmacovigilance trial of paromomycin injection for the treatment of visceral leishmaniasis in India. J Trop Med. 2011; 2011:645203. PMID: 22174722.
      View in: PubMed
    114. Kushawaha PK, Gupta R, Sundar S, Sahasrabuddhe AA, Dube A. Elongation factor-2, a Th1 stimulatory protein of Leishmania donovani, generates strong IFN-? and IL-12 response in cured Leishmania-infected patients/hamsters and protects hamsters against Leishmania challenge. J Immunol. 2011 Dec 15; 187(12):6417-27. PMID: 22079980.
      View in: PubMed
    115. Downregulation of mitogen-activated protein kinase 1 of Leishmania donovani field isolates is associated with antimony resistance. Antimicrob Agents Chemother. 2012 Jan; 56(1):518-25. PMID: 22064540.
      View in: PubMed
    116. Weirather JL, Jeronimo SM, Gautam S, Sundar S, Kang M, Kurtz MA, Haque R, Schriefer A, Talhari S, Carvalho EM, Donelson JE, Wilson ME. Serial quantitative PCR assay for detection, species discrimination, and quantification of Leishmania spp. in human samples. J Clin Microbiol. 2011 Nov; 49(11):3892-904. PMID: 22042830.
      View in: PubMed
    117. Downing T, Imamura H, Decuypere S, Clark TG, Coombs GH, Cotton JA, Hilley JD, de Doncker S, Maes I, Mottram JC, Quail MA, Rijal S, Sanders M, Schönian G, Stark O, Sundar S, Vanaerschot M, Hertz-Fowler C, Dujardin JC, Berriman M. Whole genome sequencing of multiple Leishmania donovani clinical isolates provides insights into population structure and mechanisms of drug resistance. Genome Res. 2011 Dec; 21(12):2143-56. PMID: 22038251.
      View in: PubMed
    118. Ostyn B, Gidwani K, Khanal B, Picado A, Chappuis F, Singh SP, Rijal S, Sundar S, Boelaert M. Incidence of symptomatic and asymptomatic Leishmania donovani infections in high-endemic foci in India and Nepal: a prospective study. PLoS Negl Trop Dis. 2011 Oct; 5(10):e1284. PMID: 21991397.
      View in: PubMed
    119. Gautam S, Kumar R, Maurya R, Nylén S, Ansari N, Rai M, Sundar S, Sacks D. IL-10 neutralization promotes parasite clearance in splenic aspirate cells from patients with visceral leishmaniasis. J Infect Dis. 2011 Oct 01; 204(7):1134-7. PMID: 21881130.
      View in: PubMed
    120. Perry MR, Wyllie S, Prajapati VK, Feldmann J, Sundar S, Boelaert M, Fairlamb AH. Visceral leishmaniasis and arsenic: an ancient poison contributing to antimonial treatment failure in the Indian subcontinent? PLoS Negl Trop Dis. 2011 Sep; 5(9):e1227. PMID: 21980542.
      View in: PubMed
    121. Kumar D, Kumar S, Chakravarty J, Sundar S. A novel 12.6-kDa protein of Leishmania donovani for the diagnosis of Indian visceral leishmaniasis. Vector Borne Zoonotic Dis. 2011 Oct; 11(10):1359-64. PMID: 21923256.
      View in: PubMed
    122. Gidwani K, Picado A, Rijal S, Singh SP, Roy L, Volfova V, Andersen EW, Uranw S, Ostyn B, Sudarshan M, Chakravarty J, Volf P, Sundar S, Boelaert M, Rogers ME. Serological markers of sand fly exposure to evaluate insecticidal nets against visceral leishmaniasis in India and Nepal: a cluster-randomized trial. PLoS Negl Trop Dis. 2011 Sep; 5(9):e1296. PMID: 21931871.
      View in: PubMed
    123. Mukhopadhyay R, Mukherjee S, Mukherjee B, Naskar K, Mondal D, Decuypere S, Ostyn B, Prajapati VK, Sundar S, Dujardin JC, Roy S. Characterisation of antimony-resistant Leishmania donovani isolates: biochemical and biophysical studies and interaction with host cells. Int J Parasitol. 2011 Nov; 41(13-14):1311-21. PMID: 21920365.
      View in: PubMed
    124. Kumar P, Kumar R, Pandey H, Sundar S, Pai K. Studies on the arginase, 5'-nucleotidase and lysozyme activity by monocytes from visceral leishmaniasis patients. J Parasit Dis. 2012 Apr; 36(1):19-25. PMID: 23542635.
      View in: PubMed
    125. Kumar N, Singh SP, Mondal D, Joshi A, Das P, Sundar S, Kroeger A, Hirve S, Siddiqui NA, Boelaert M. How do health care providers deal with kala-azar in the Indian subcontinent? Indian J Med Res. 2011 Sep; 134:349-55. PMID: 21985818.
      View in: PubMed
    126. Srivastava P, Singh T, Sundar S. Genetic heterogeneity in clinical isolates of Leishmania donovani from India. J Clin Microbiol. 2011 Oct; 49(10):3687-90. PMID: 21865422.
      View in: PubMed
    127. Fakiola M, Miller EN, Fadl M, Mohamed HS, Jamieson SE, Francis RW, Cordell HJ, Peacock CS, Raju M, Khalil EA, Elhassan A, Musa AM, Silveira F, Shaw JJ, Sundar S, Jeronimo SM, Ibrahim ME, Blackwell JM. Genetic and functional evidence implicating DLL1 as the gene that influences susceptibility to visceral leishmaniasis at chromosome 6q27. J Infect Dis. 2011 Aug 01; 204(3):467-77. PMID: 21742847.
      View in: PubMed
    128. Chakravarty J, Kumar S, Kumar R, Gautam S, Rai M, Sundar S. Evaluation of rk39 immunochromatographic test with urine for diagnosis of visceral leishmaniasis. Trans R Soc Trop Med Hyg. 2011 Sep; 105(9):537-9. PMID: 21708392.
      View in: PubMed
    129. Kumar R, Sundar S, Sharma P, Sarin SK. Conservative management of liver abscess complicated by hepatogastric fistula. Dig Liver Dis. 2011 Sep; 43(9):752-3. PMID: 21641891.
      View in: PubMed
    130. Meena LP, Rai M, Singh SK, Chakravarty J, Singh A, Goel R, Pathak A, Sundar S. Endocrine changes in male HIV patients. J Assoc Physicians India. 2011 Jun; 59:365-6, 371. PMID: 21751590.
      View in: PubMed
    131. Sundar S, Sinha PK, Dixon SA, Buckley R, Miller AK, Mohamed K, Al-Banna M. Pharmacokinetics of oral sitamaquine taken with or without food and safety and efficacy for treatment of visceral leishmaniais: a randomized study in Bihar, India. Am J Trop Med Hyg. 2011 Jun; 84(6):892-900. PMID: 21633025.
      View in: PubMed
    132. Mohan S, Srivastava P, Maheshwari SN, Sundar S, Prakash R. Nano-structured nickel oxide based DNA biosensor for detection of visceral leishmaniasis (Kala-azar). Analyst. 2011 Jul 07; 136(13):2845-51. PMID: 21611668.
      View in: PubMed
    133. Srivastava P, Prajapati VK, Rai M, Sundar S. Unusual case of resistance to amphotericin B in visceral leishmaniasis in a region in India where leishmaniasis is not endemic. J Clin Microbiol. 2011 Aug; 49(8):3088-91. PMID: 21613432.
      View in: PubMed
    134. Sudarshan M, Weirather JL, Wilson ME, Sundar S. Study of parasite kinetics with antileishmanial drugs using real-time quantitative PCR in Indian visceral leishmaniasis. J Antimicrob Chemother. 2011 Aug; 66(8):1751-5. PMID: 21609983.
      View in: PubMed
    135. Mehrotra S, Oommen J, Mishra A, Sudharshan M, Tiwary P, Jamieson SE, Fakiola M, Rani DS, Thangaraj K, Rai M, Sundar S, Blackwell JM. No evidence for association between SLC11A1 and visceral leishmaniasis in India. BMC Med Genet. 2011 May 20; 12:71. PMID: 21599885.
      View in: PubMed
    136. Srivastava P, Mehrotra S, Tiwary P, Chakravarty J, Sundar S. Diagnosis of Indian visceral leishmaniasis by nucleic acid detection using PCR. PLoS One. 2011 Apr 29; 6(4):e19304. PMID: 21559398.
      View in: PubMed
    137. Gidwani K, Jones S, Kumar R, Boelaert M, Sundar S. Interferon-gamma release assay (modified QuantiFERON) as a potential marker of infection for Leishmania donovani, a proof of concept study. PLoS Negl Trop Dis. 2011 Apr 19; 5(4):e1042. PMID: 21526219.
      View in: PubMed
    138. Matlashewski G, Arana B, Kroeger A, Battacharya S, Sundar S, Das P, Sinha PK, Rijal S, Mondal D, Zilberstein D, Alvar J. Visceral leishmaniasis: elimination with existing interventions. Lancet Infect Dis. 2011 Apr; 11(4):322-5. PMID: 21453873.
      View in: PubMed
    139. Harhay MO, Olliaro PL, Vaillant M, Chappuis F, Lima MA, Ritmeijer K, Costa CH, Costa DL, Rijal S, Sundar S, Balasegaram M. Who is a typical patient with visceral leishmaniasis? Characterizing the demographic and nutritional profile of patients in Brazil, East Africa, and South Asia. Am J Trop Med Hyg. 2011 Apr; 84(4):543-50. PMID: 21460007.
      View in: PubMed
    140. Kumar S, Kumar D, Chakravarty J, Sundar S. Identification and Characterization of a Novel, 37-Kilodalton Leishmania donovani antigen for diagnosis of Indian visceral leishmaniasis. Clin Vaccine Immunol. 2011 May; 18(5):772-5. PMID: 21411602.
      View in: PubMed
    141. Chakravarty J, Kumar S, Trivedi S, Rai VK, Singh A, Ashman JA, Laughlin EM, Coler RN, Kahn SJ, Beckmann AM, Cowgill KD, Reed SG, Sundar S, Piazza FM. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis. Vaccine. 2011 Apr 27; 29(19):3531-7. PMID: 21414377.
      View in: PubMed
    142. Vaish M, Mehrotra S, Chakravarty J, Sundar S. Noninvasive molecular diagnosis of human visceral leishmaniasis. J Clin Microbiol. 2011 May; 49(5):2003-5. PMID: 21389158.
      View in: PubMed
    143. Malaviya P, Picado A, Singh SP, Hasker E, Singh RP, Boelaert M, Sundar S. Visceral leishmaniasis in Muzaffarpur district, Bihar, India from 1990 to 2008. PLoS One. 2011 Mar 04; 6(3):e14751. PMID: 21394195.
      View in: PubMed
    144. Ansari NA, Kumar R, Gautam S, Nylén S, Singh OP, Sundar S, Sacks D. IL-27 and IL-21 are associated with T cell IL-10 responses in human visceral leishmaniasis. J Immunol. 2011 Apr 01; 186(7):3977-85. PMID: 21357266.
      View in: PubMed
    145. Singh SP, Hirve S, Huda MM, Banjara MR, Kumar N, Mondal D, Sundar S, Das P, Gurung CK, Rijal S, Thakur CP, Varghese B, Kroeger A. Options for active case detection of visceral leishmaniasis in endemic districts of India, Nepal and Bangladesh, comparing yield, feasibility and costs. PLoS Negl Trop Dis. 2011 Feb 08; 5(2):e960. PMID: 21347452.
      View in: PubMed
    146. Prajapati VK, Awasthi K, Gautam S, Yadav TP, Rai M, Srivastava ON, Sundar S. Targeted killing of Leishmania donovani in vivo and in vitro with amphotericin B attached to functionalized carbon nanotubes. J Antimicrob Chemother. 2011 Apr; 66(4):874-9. PMID: 21393222.
      View in: PubMed
    147. Sundar S, Sinha PK, Rai M, Verma DK, Nawin K, Alam S, Chakravarty J, Vaillant M, Verma N, Pandey K, Kumari P, Lal CS, Arora R, Sharma B, Ellis S, Strub-Wourgaft N, Balasegaram M, Olliaro P, Das P, Modabber F. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. Lancet. 2011 Feb 05; 377(9764):477-86. PMID: 21255828.
      View in: PubMed
    148. Fakiola M, Mishra A, Rai M, Singh SP, O'Leary RA, Ball S, Francis RW, Firth MJ, Radford BT, Miller EN, Sundar S, Blackwell JM. Classification and regression tree and spatial analyses reveal geographic heterogeneity in genome wide linkage study of Indian visceral leishmaniasis. PLoS One. 2010 Dec 31; 5(12):e15807. PMID: 21209823.
      View in: PubMed
    149. Picado A, Singh SP, Rijal S, Sundar S, Ostyn B, Chappuis F, Uranw S, Gidwani K, Khanal B, Rai M, Paudel IS, Das ML, Kumar R, Srivastava P, Dujardin JC, Vanlerberghe V, Andersen EW, Davies CR, Boelaert M. Longlasting insecticidal nets for prevention of Leishmania donovani infection in India and Nepal: paired cluster randomised trial. BMJ. 2010 Dec 29; 341:c6760. PMID: 21190965.
      View in: PubMed
    150. Sundar S, Chakravarty J. Antimony toxicity. Int J Environ Res Public Health. 2010 12; 7(12):4267-77. PMID: 21318007.
      View in: PubMed
    151. Gidwani K, Picado A, Ostyn B, Singh SP, Kumar R, Khanal B, Lejon V, Chappuis F, Boelaert M, Sundar S. Persistence of Leishmania donovani antibodies in past visceral leishmaniasis cases in India. Clin Vaccine Immunol. 2011 Feb; 18(2):346-8. PMID: 21159922.
      View in: PubMed
    152. Sundar S, Sinha PK, Verma DK, Kumar N, Alam S, Pandey K, Kumari P, Ravidas V, Chakravarty J, Verma N, Berman J, Ghalib H, Arana B. Ambisome plus miltefosine for Indian patients with kala-azar. Trans R Soc Trop Med Hyg. 2011 Feb; 105(2):115-7. PMID: 21129762.
      View in: PubMed
    153. Srivastava P, Dayama A, Mehrotra S, Sundar S. Diagnosis of visceral leishmaniasis. Trans R Soc Trop Med Hyg. 2011 Jan; 105(1):1-6. PMID: 21074233.
      View in: PubMed
    154. Dujardin JC, Herrera S, do Rosario V, Arevalo J, Boelaert M, Carrasco HJ, Correa-Oliveira R, Garcia L, Gotuzzo E, Gyorkos TW, Kalergis AM, Kouri G, Larraga V, Lutumba P, Macias Garcia MA, Manrique-Saide PC, Modabber F, Nieto A, Pluschke G, Robello C, Rojas de Arias A, Rumbo M, Santos Preciado JI, Sundar S, Torres J, Torrico F, Van der Stuyft P, Victoir K, Olesen OF. Research priorities for neglected infectious diseases in Latin America and the Caribbean region. PLoS Negl Trop Dis. 2010 Oct 26; 4(10):e780. PMID: 21049009.
      View in: PubMed
    155. Kumar A, Sisodia B, Misra P, Sundar S, Shasany AK, Dube A. Proteome mapping of overexpressed membrane-enriched and cytosolic proteins in sodium antimony gluconate (SAG) resistant clinical isolate of Leishmania donovani. Br J Clin Pharmacol. 2010 Oct; 70(4):609-17. PMID: 20840452.
      View in: PubMed
    156. Agarwal D, Chakravarty J, Chaube L, Rai M, Agrawal NR, Sundar S. High incidence of zidovudine induced anaemia in HIV infected patients in eastern India. Indian J Med Res. 2010 Oct; 132:386-9. PMID: 20966515.
      View in: PubMed
    157. Meheus F, Balasegaram M, Olliaro P, Sundar S, Rijal S, Faiz MA, Boelaert M. Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent. PLoS Negl Trop Dis. 2010 Sep 07; 4(9). PMID: 20838649.
      View in: PubMed
    158. Hirve S, Singh SP, Kumar N, Banjara MR, Das P, Sundar S, Rijal S, Joshi A, Kroeger A, Varghese B, Thakur CP, Huda MM, Mondal D. Effectiveness and feasibility of active and passive case detection in the visceral leishmaniasis elimination initiative in India, Bangladesh, and Nepal. Am J Trop Med Hyg. 2010 Sep; 83(3):507-11. PMID: 20810811.
      View in: PubMed
    159. Srivastava P, Prajapati VK, Vanaerschot M, Van der Auwera G, Dujardin JC, Sundar S. Detection of Leptomonas sp. parasites in clinical isolates of Kala-azar patients from India. Infect Genet Evol. 2010 Oct; 10(7):1145-50. PMID: 20633704.
      View in: PubMed
    160. Agarwal D, Narayan S, Chakravarty J, Sundar S. Ultrasonography for diagnosis of abdominal tuberculosis in HIV infected people. Indian J Med Res. 2010 Jul; 132:77-80. PMID: 20693594.
      View in: PubMed
    161. Mishra RN, Singh SP, Vanlerberghe V, Sundar S, Boelaert M, Lefèvre P. Lay perceptions of kala-azar, mosquitoes and bed nets in Bihar, India. Trop Med Int Health. 2010 Jul; 15 Suppl 2:36-41. PMID: 20591080.
      View in: PubMed
    162. Kaur J, Sundar S, Singh N. Molecular docking, structure-activity relationship and biological evaluation of the anticancer drug monastrol as a pteridine reductase inhibitor in a clinical isolate of Leishmania donovani. J Antimicrob Chemother. 2010 Aug; 65(8):1742-8. PMID: 20519355.
      View in: PubMed
    163. Wyllie S, Mandal G, Singh N, Sundar S, Fairlamb AH, Chatterjee M. Elevated levels of tryparedoxin peroxidase in antimony unresponsive Leishmania donovani field isolates. Mol Biochem Parasitol. 2010 Oct; 173(2):162-4. PMID: 20553768.
      View in: PubMed
    164. Singh SP, Picado A, Boelaert M, Gidwani K, Andersen EW, Ostyn B, Meheus F, Rai M, Chappuis F, Davies C, Sundar S. The epidemiology of Leishmania donovani infection in high transmission foci in India. Trop Med Int Health. 2010 Jul; 15 Suppl 2:12-20. PMID: 20487420.
      View in: PubMed
    165. Sundar S, Arora R, Singh SP, Boelaert M, Varghese B. Household cost-of-illness of visceral leishmaniasis in Bihar, India. Trop Med Int Health. 2010 Jul; 15 Suppl 2:50-4. PMID: 20487419.
      View in: PubMed
    166. Clements MF, Gidwani K, Kumar R, Hostomska J, Dinesh DS, Kumar V, Das P, Müller I, Hamilton G, Volfova V, Boelaert M, Das M, Rijal S, Picado A, Volf P, Sundar S, Davies CR, Rogers ME. Measurement of recent exposure to Phlebotomus argentipes, the vector of Indian visceral Leishmaniasis, by using human antibody responses to sand fly saliva. Am J Trop Med Hyg. 2010 May; 82(5):801-7. PMID: 20439958.
      View in: PubMed
    167. Kumar R, Goto Y, Gidwani K, Cowgill KD, Sundar S, Reed SG. Evaluation of ex vivo human immune response against candidate antigens for a visceral leishmaniasis vaccine. Am J Trop Med Hyg. 2010 May; 82(5):808-13. PMID: 20439959.
      View in: PubMed
    168. Sundar S, Chakravarty J. Liposomal amphotericin B and leishmaniasis: dose and response. J Glob Infect Dis. 2010 May; 2(2):159-66. PMID: 20606972.
      View in: PubMed
    169. Chakravarty J, Sundar S. Drug resistance in leishmaniasis. J Glob Infect Dis. 2010 May; 2(2):167-76. PMID: 20606973.
      View in: PubMed
    170. Maurya R, Mehrotra S, Prajapati VK, Nylén S, Sacks D, Sundar S. Evaluation of blood agar microtiter plates for culturing leishmania parasites to titrate parasite burden in spleen and peripheral blood of patients with visceral leishmaniasis. J Clin Microbiol. 2010 May; 48(5):1932-4. PMID: 20335419.
      View in: PubMed
    171. Mohapatra TM, Singh DP, Sen MR, Bharti K, Sundar S. Compararative evaluation of rK9, rK26 and rK39 antigens in the serodiagnosis of Indian visceral leishmaniasis. J Infect Dev Ctries. 2010 Mar 08; 4(2):114-7. PMID: 20212344.
      View in: PubMed
    172. Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med. 2010 Feb 11; 362(6):504-12. PMID: 20147716.
      View in: PubMed
    173. Picado A, Das ML, Kumar V, Kesari S, Dinesh DS, Roy L, Rijal S, Das P, Rowland M, Sundar S, Coosemans M, Boelaert M, Davies CR. Effect of village-wide use of long-lasting insecticidal nets on visceral Leishmaniasis vectors in India and Nepal: a cluster randomized trial. PLoS Negl Trop Dis. 2010 Jan 26; 4(1):e587. PMID: 20126269.
      View in: PubMed
    174. Tuli L, Singh DK, Gulati AK, Sundar S, Mohapatra TM. A multiattribute utility evaluation of different methods for the detection of enteric protozoa causing diarrhea in AIDS patients. BMC Microbiol. 2010 Jan 15; 10:11. PMID: 20078872.
      View in: PubMed
    175. Picado A, Kumar V, Das M, Burniston I, Roy L, Suman R, Dinesh D, Coosemans M, Sundar S, Shreekant K, Boelaert M, Davies C, Cameron M. Effect of untreated bed nets on blood-fed Phlebotomus argentipes in kala-azar endemic foci in Nepal and India. Mem Inst Oswaldo Cruz. 2009 Dec; 104(8):1183-6. PMID: 20140382.
      View in: PubMed
    176. Kumar A, Boggula VR, Misra P, Sundar S, Shasany AK, Dube A. Amplified fragment length polymorphism (AFLP) analysis is useful for distinguishing Leishmania species of visceral and cutaneous forms. Acta Trop. 2010 Feb; 113(2):202-6. PMID: 19854144.
      View in: PubMed
    177. Singh DP, Sundar S, Mohapatra TM. The rK39 strip test is non-predictor of clinical status for kala-azar. BMC Res Notes. 2009 Sep 22; 2:187. PMID: 19772616.
      View in: PubMed
    178. Sundar S, Agrawal N, Arora R, Agarwal D, Rai M, Chakravarty J. Short-course paromomycin treatment of visceral leishmaniasis in India: 14-day vs 21-day treatment. Clin Infect Dis. 2009 Sep 15; 49(6):914-8. PMID: 19663597.
      View in: PubMed
    179. Olliaro P, Darley S, Laxminarayan R, Sundar S. Cost-effectiveness projections of single and combination therapies for visceral leishmaniasis in Bihar, India. Trop Med Int Health. 2009 Aug; 14(8):918-25. PMID: 19563434.
      View in: PubMed
    180. Singh N, Gupta R, Jaiswal AK, Sundar S, Dube A. Transgenic Leishmania donovani clinical isolates expressing green fluorescent protein constitutively for rapid and reliable ex vivo drug screening. J Antimicrob Chemother. 2009 Aug; 64(2):370-4. PMID: 19525291.
      View in: PubMed
    181. Sundar S, Singh A, Agarwal D, Rai M, Agrawal N, Chakravarty J. Safety and efficacy of high-dose infusions of a preformed amphotericin B fat emulsion for treatment of Indian visceral leishmaniasis. Am J Trop Med Hyg. 2009 May; 80(5):700-3. PMID: 19407109.
      View in: PubMed
    182. Sarkar A, Mandal G, Singh N, Sundar S, Chatterjee M. Flow cytometric determination of intracellular non-protein thiols in Leishmania promastigotes using 5-chloromethyl fluorescein diacetate. Exp Parasitol. 2009 Aug; 122(4):299-305. PMID: 19393240.
      View in: PubMed
    183. Kumar A, Boggula VR, Sundar S, Shasany AK, Dube A. Identification of genetic markers in sodium antimony gluconate (SAG) sensitive and resistant Indian clinical isolates of Leishmania donovani through amplified fragment length polymorphism (AFLP). Acta Trop. 2009 Apr; 110(1):80-5. PMID: 19283900.
      View in: PubMed
    184. Gidwani K, Rai M, Chakravarty J, Boelaert M, Sundar S. Evaluation of leishmanin skin test in Indian visceral leishmaniasis. Am J Trop Med Hyg. 2009 Apr; 80(4):566-7. PMID: 19346376.
      View in: PubMed
    185. Gidwani K, Kumar R, Rai M, Sundar S. Longitudinal seroepidemiologic study of visceral leishmaniasis in hyperendemic regions of Bihar, India. Am J Trop Med Hyg. 2009 Mar; 80(3):345-6. PMID: 19270279.
      View in: PubMed
    186. Mandal G, Sarkar A, Saha P, Singh N, Sundar S, Chatterjee M. Functionality of drug efflux pumps in antimonial resistant Leishmania donovani field isolates. Indian J Biochem Biophys. 2009 Feb; 46(1):86-92. PMID: 19374259.
      View in: PubMed
    187. Ghoshal A, Mukhopadhyay S, Demine R, Forgber M, Jarmalavicius S, Saha B, Sundar S, Walden P, Mandal C, Mandal C. Detection and characterization of a sialoglycosylated bacterial ABC-type phosphate transporter protein from patients with visceral leishmaniasis. Glycoconj J. 2009 Aug; 26(6):675-89. PMID: 19184417.
      View in: PubMed
    188. Mondal D, Singh SP, Kumar N, Joshi A, Sundar S, Das P, Siddhivinayak H, Kroeger A, Boelaert M. Visceral leishmaniasis elimination programme in India, Bangladesh, and Nepal: reshaping the case finding/case management strategy. PLoS Negl Trop Dis. 2009; 3(1):e355. PMID: 19159009.
      View in: PubMed
    189. Olliaro P, Sundar S. Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India. Trop Med Int Health. 2009 Jan; 14(1):88-92. PMID: 19121150.
      View in: PubMed
    190. Trudel N, Garg R, Messier N, Sundar S, Ouellette M, Tremblay MJ. Intracellular survival of Leishmania species that cause visceral leishmaniasis is significantly reduced by HIV-1 protease inhibitors. J Infect Dis. 2008 Nov 01; 198(9):1292-9. PMID: 18816190.
      View in: PubMed
    191. Sundar S, Rai M, Chakravarty J, Agarwal D, Agrawal N, Vaillant M, Olliaro P, Murray HW. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine. Clin Infect Dis. 2008 Oct 15; 47(8):1000-6. PMID: 18781879.
      View in: PubMed
    192. Alam MZ, Kuhls K, Schweynoch C, Sundar S, Rijal S, Shamsuzzaman AK, Raju BV, Salotra P, Dujardin JC, Schönian G. Multilocus microsatellite typing (MLMT) reveals genetic homogeneity of Leishmania donovani strains in the Indian subcontinent. Infect Genet Evol. 2009 Jan; 9(1):24-31. PMID: 18957333.
      View in: PubMed
    193. Tuli L, Gulati AK, Sundar S, Mohapatra TM. Correlation between CD4 counts of HIV patients and enteric protozoan in different seasons - an experience of a tertiary care hospital in Varanasi (India). BMC Gastroenterol. 2008 Aug 20; 8:36. PMID: 18713475.
      View in: PubMed
    194. Sundar S, Chakravarty J, Agarwal D, Shah A, Agrawal N, Rai M. Safety of a pre-formulated amphotericin B lipid emulsion for the treatment of Indian Kala-azar. Trop Med Int Health. 2008 Sep; 13(9):1208-12. PMID: 18664241.
      View in: PubMed
    195. Kumari S, Samant M, Khare P, Sundar S, Sinha S, Dube A. Induction of Th1-type cellular responses in cured/exposed Leishmania-infected patients and hamsters against polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1 kDa. Vaccine. 2008 Sep 02; 26(37):4813-8. PMID: 18656517.
      View in: PubMed
    196. Ostyn B, Vanlerberghe V, Picado A, Dinesh DS, Sundar S, Chappuis F, Rijal S, Dujardin JC, Coosemans M, Boelaert M, Davies C. Vector control by insecticide-treated nets in the fight against visceral leishmaniasis in the Indian subcontinent, what is the evidence? Trop Med Int Health. 2008 Aug; 13(8):1073-85. PMID: 18564350.
      View in: PubMed
    197. Manandhar KD, Yadav TP, Prajapati VK, Kumar S, Rai M, Dube A, Srivastava ON, Sundar S. Antileishmanial activity of nano-amphotericin B deoxycholate. J Antimicrob Chemother. 2008 Aug; 62(2):376-80. PMID: 18453526.
      View in: PubMed
    198. Sundar S, Chakravarty J. Paromomycin in the treatment of leishmaniasis. Expert Opin Investig Drugs. 2008 May; 17(5):787-94. PMID: 18447603.
      View in: PubMed
    199. Kumari S, Kumar A, Samant M, Sundar S, Singh N, Dube A. Proteomic approaches for discovery of new targets for vaccine and therapeutics against visceral leishmaniasis. Proteomics Clin Appl. 2008 Mar; 2(3):372-86. PMID: 21136840.
      View in: PubMed
    200. Sundar S, Mondal D, Rijal S, Bhattacharya S, Ghalib H, Kroeger A, Boelaert M, Desjeux P, Richter-Airijoki H, Harms G. Implementation research to support the initiative on the elimination of kala azar from Bangladesh, India and Nepal--the challenges for diagnosis and treatment. Trop Med Int Health. 2008 Jan; 13(1):2-5. PMID: 18290995.
      View in: PubMed
    201. Das ML, Singh SP, Vanlerberghe V, Rijal S, Rai M, Karki P, Sundar S, Boelaert M. Population preference of net texture prior to bed net trial in Kala-Azar-endemic areas. PLoS Negl Trop Dis. 2007 Dec 12; 1(3):e100. PMID: 18160976.
      View in: PubMed
    202. Mookerjee Basu J, Mookerjee A, Banerjee R, Saha M, Singh S, Naskar K, Tripathy G, Sinha PK, Pandey K, Sundar S, Bimal S, Das PK, Choudhuri SK, Roy S. Inhibition of ABC transporters abolishes antimony resistance in Leishmania Infection. Antimicrob Agents Chemother. 2008 Mar; 52(3):1080-93. PMID: 18056276.
      View in: PubMed
    203. Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, Peeling RW, Alvar J, Boelaert M. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol. 2007 Nov; 5(11):873-82. PMID: 17938629.
      View in: PubMed
    204. Tripathi K, Kumar R, Bharti K, Kumar P, Shrivastav R, Sundar S, Pai K. Adenosine deaminase activity in sera of patients with visceral leishmaniasis in India. Clin Chim Acta. 2008 Feb; 388(1-2):135-8. PMID: 18023276.
      View in: PubMed
    205. Boelaert M, El-Safi S, Hailu A, Mukhtar M, Rijal S, Sundar S, Wasunna M, Aseffa A, Mbui J, Menten J, Desjeux P, Peeling RW. Diagnostic tests for kala-azar: a multi-centre study of the freeze-dried DAT, rK39 strip test and KAtex in East Africa and the Indian subcontinent. Trans R Soc Trop Med Hyg. 2008 Jan; 102(1):32-40. PMID: 17942129.
      View in: PubMed
    206. Sundar S, Olliaro PL. Miltefosine in the treatment of leishmaniasis: Clinical evidence for informed clinical risk management. Ther Clin Risk Manag. 2007 Oct; 3(5):733-40. PMID: 18472998.
      View in: PubMed
    207. Sundar S, Chakravarty J, Rai VK, Agrawal N, Singh SP, Chauhan V, Murray HW. Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions. Clin Infect Dis. 2007 Sep 01; 45(5):556-61. PMID: 17682988.
      View in: PubMed
    208. Bhattacharya SK, Sinha PK, Sundar S, Thakur CP, Jha TK, Pandey K, Das VR, Kumar N, Lal C, Verma N, Singh VP, Ranjan A, Verma RB, Anders G, Sindermann H, Ganguly NK. Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. J Infect Dis. 2007 Aug 15; 196(4):591-8. PMID: 17624846.
      View in: PubMed
    209. Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK. Injectable paromomycin for Visceral leishmaniasis in India. N Engl J Med. 2007 Jun 21; 356(25):2571-81. PMID: 17582067.
      View in: PubMed
    210. Mittal MK, Rai S. Characterization of natural antimony resistance in Leishmania donovani isolates. Am J Trop Med Hyg. 2007 Apr; 76(4):681-8. PMID: 17426170.
      View in: PubMed
    211. Nylén S, Maurya R, Eidsmo L, Manandhar KD, Sundar S, Sacks D. Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T cells in human visceral leishmaniasis. J Exp Med. 2007 Apr 16; 204(4):805-17. PMID: 17389235.
      View in: PubMed
    212. Sundar S, Singh RK, Bimal SK, Gidwani K, Mishra A, Maurya R, Singh SK, Manandhar KD, Boelaert M, Rai M. Comparative evaluation of parasitology and serological tests in the diagnosis of visceral leishmaniasis in India: a phase III diagnostic accuracy study. Trop Med Int Health. 2007 Feb; 12(2):284-9. PMID: 17300637.
      View in: PubMed
    213. Molecular mechanisms of antimony resistance in Leishmania. J Med Microbiol. 2007 Feb; 56(Pt 2):143-53. PMID: 17244793.
      View in: PubMed
    214. Forgber M, Basu R, Roychoudhury K, Theinert S, Roy S, Sundar S, Walden P. Mapping the antigenicity of the parasites in Leishmania donovani infection by proteome serology. PLoS One. 2006 Dec 20; 1:e40. PMID: 17183669.
      View in: PubMed
    215. Kothari H, Kumar P, Sundar S, Singh N. Possibility of membrane modification as a mechanism of antimony resistance in Leishmania donovani. Parasitol Int. 2007 Mar; 56(1):77-80. PMID: 17169604.
      View in: PubMed
    216. Jacquet D, Boelaert M, Seaman J, Rijal S, Sundar S, Menten J, Magnus E. Comparative evaluation of freeze-dried and liquid antigens in the direct agglutination test for serodiagnosis of visceral leishmaniasis (ITMA-DAT/VL). Trop Med Int Health. 2006 Dec; 11(12):1777-84. PMID: 17176341.
      View in: PubMed
    217. Meheus F, Boelaert M, Baltussen R, Sundar S. Costs of patient management of visceral leishmaniasis in Muzaffarpur, Bihar, India. Trop Med Int Health. 2006 Nov; 11(11):1715-24. PMID: 17054752.
      View in: PubMed
    218. Vergnes B, Gourbal B, Girard I, Sundar S, Drummelsmith J, Ouellette M. A proteomics screen implicates HSP83 and a small kinetoplastid calpain-related protein in drug resistance in Leishmania donovani clinical field isolates by modulating drug-induced programmed cell death. Mol Cell Proteomics. 2007 Jan; 6(1):88-101. PMID: 17050524.
      View in: PubMed
    219. Shrivastava R, Sinha PR, Singh VP, Sundar S. Echocardiographic evaluation of cardiac status in Indian visceral leishmaniasis patients. Trans R Soc Trop Med Hyg. 2007 May; 101(5):429-32. PMID: 17049574.
      View in: PubMed
    220. Lockwood DN, Sundar S. Serological tests for visceral leishmaniasis. BMJ. 2006 Oct 07; 333(7571):711-2. PMID: 17023436.
      View in: PubMed
    221. Singh SP, Reddy DC, Mishra RN, Sundar S. Knowledge, attitude, and practices related to Kala-azar in a rural area of Bihar state, India. Am J Trop Med Hyg. 2006 Sep; 75(3):505-8. PMID: 16968930.
      View in: PubMed
    222. Bern C, Adler-Moore J, Berenguer J, Boelaert M, den Boer M, Davidson RN, Figueras C, Gradoni L, Kafetzis DA, Ritmeijer K, Rosenthal E, Royce C, Russo R, Sundar S, Alvar J. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis. 2006 Oct 01; 43(7):917-24. PMID: 16941377.
      View in: PubMed
    223. Berman J, Bryceson AD, Croft S, Engel J, Gutteridge W, Karbwang J, Sindermann H, Soto J, Sundar S, Urbina JA. Miltefosine: issues to be addressed in the future. Trans R Soc Trop Med Hyg. 2006 Dec; 100 Suppl 1:S41-4. PMID: 16750231.
      View in: PubMed
    224. Singh SP, Reddy DC, Rai M, Sundar S. Serious underreporting of visceral leishmaniasis through passive case reporting in Bihar, India. Trop Med Int Health. 2006 Jun; 11(6):899-905. PMID: 16772012.
      View in: PubMed
    225. Sundar S, Jha TK, Thakur CP, Bhattacharya SK, Rai M. Oral miltefosine for the treatment of Indian visceral leishmaniasis. Trans R Soc Trop Med Hyg. 2006 Dec; 100 Suppl 1:S26-33. PMID: 16730038.
      View in: PubMed
    226. Sundar S, Chatterjee M. Visceral leishmaniasis - current therapeutic modalities. Indian J Med Res. 2006 Mar; 123(3):345-52. PMID: 16778315.
      View in: PubMed
    227. Attili SV, Gulati AK, Singh VP, Varma DV, Rai M, Sundar S. Diarrhea, CD4 counts and enteric infections in a hospital - based cohort of HIV-infected patients around Varanasi, India. BMC Infect Dis. 2006 Mar 01; 6:39. PMID: 16509972.
      View in: PubMed
    228. Pérez-Victoria FJ, Sánchez-Cañete MP, Seifert K, Croft SL, Sundar S, Castanys S, Gamarro F. Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use. Drug Resist Updat. 2006 Feb-Apr; 9(1-2):26-39. PMID: 16814199.
      View in: PubMed
    229. Sundar S, Mehta H, Chhabra A, Singh V, Chauhan V, Desjeux P, Rai M. Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis. Clin Infect Dis. 2006 Mar 01; 42(5):608-13. PMID: 16447104.
      View in: PubMed
    230. Sundar S, Maurya R, Singh RK, Bharti K, Chakravarty J, Parekh A, Rai M, Kumar K, Murray HW. Rapid, noninvasive diagnosis of visceral leishmaniasis in India: comparison of two immunochromatographic strip tests for detection of anti-K39 antibody. J Clin Microbiol. 2006 Jan; 44(1):251-3. PMID: 16390983.
      View in: PubMed
    231. Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev. 2006 Jan; 19(1):111-26. PMID: 16418526.
      View in: PubMed
    232. Sundar S, Kumar K, Chakravarty J, Agrawal D, Agrawal S, Chhabra A, Singh V. Cure of antimony-unresponsive Indian post-kala-azar dermal leishmaniasis with oral miltefosine. Trans R Soc Trop Med Hyg. 2006 Jul; 100(7):698-700. PMID: 16325873.
      View in: PubMed
    233. Sundar S, Rai M. Treatment of visceral leishmaniasis. Expert Opin Pharmacother. 2005 Dec; 6(16):2821-9. PMID: 16318433.
      View in: PubMed
    234. Olliaro PL, Guerin PJ, Gerstl S, Haaskjold AA, Rottingen JA, Sundar S. Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. Lancet Infect Dis. 2005 Dec; 5(12):763-74. PMID: 16310148.
      View in: PubMed
    235. Jha TK, Sundar S, Thakur CP, Felton JM, Sabin AJ, Horton J. A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India. Am J Trop Med Hyg. 2005 Dec; 73(6):1005-11. PMID: 16354802.
      View in: PubMed
    236. Theinert SM, Basu R, Forgber M, Roy S, Sundar S, Walden P. Identification of new antigens in visceral leishmaniasis by expression cloning and immunoblotting with sera of kala-azar patients from Bihar, India. Infect Immun. 2005 Oct; 73(10):7018-21. PMID: 16177384.
      View in: PubMed
    237. Barnett PG, Singh SP, Bern C, Hightower AW, Sundar S. Virgin soil: the spread of visceral leishmaniasis into Uttar Pradesh, India. Am J Trop Med Hyg. 2005 Oct; 73(4):720-5. PMID: 16222016.
      View in: PubMed
    238. Use of Leishmania donovani field isolates expressing the luciferase reporter gene in in vitro drug screening. Antimicrob Agents Chemother. 2005 Sep; 49(9):3776-83. PMID: 16131481.
      View in: PubMed
    239. Sundar S, Agrawal S, Pai K, Chance M, Hommel M. Detection of leishmanial antigen in the urine of patients with visceral leishmaniasis by a latex agglutination test. Am J Trop Med Hyg. 2005 Aug; 73(2):269-71. PMID: 16103587.
      View in: PubMed
    240. Attili VS, Sundar S, Singh VP, Rai M. Validity of existing CD4+ classification in north Indians, in predicting immune status. J Infect. 2005 Jul; 51(1):41-6. PMID: 15979490.
      View in: PubMed
    241. Manna M, Majumder HK, Sundar S, Bhaduri AN. The molecular characterization of clinical isolates from Indian Kala-azar patients by MLEE and RAPD-PCR. Med Sci Monit. 2005 Jul; 11(7):BR220-7. PMID: 15990683.
      View in: PubMed
    242. Sundar S, Murray HW. Availability of miltefosine for the treatment of kala-azar in India. Bull World Health Organ. 2005 May; 83(5):394-5. PMID: 15976883.
      View in: PubMed
    243. Sundar S, Kumar A. Challenges in the management of visceral leishmaniasis. Indian Pediatr. 2005 Jun; 42(6):523-6. PMID: 15995268.
      View in: PubMed
    244. Dube A, Singh N, Sundar S, Singh N. Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models. Parasitol Res. 2005 Jun; 96(4):216-23. PMID: 15868188.
      View in: PubMed
    245. Bandyopadhyay S, Chatterjee M, Das T, Bandyopadhyay S, Sundar S, Mandal C. Antibodies directed against O-acetylated sialoglycoconjugates accelerate complement activation in Leishmania donovani promastigotes. J Infect Dis. 2004 Dec 01; 190(11):2010-9. PMID: 15529267.
      View in: PubMed
    246. Bandyopadhyay S, Chatterjee M, Pal S, Waller RF, Sundar S, McConville MJ, Mandal C. Purification, characterization of O-acetylated sialoglycoconjugates-specific IgM, and development of an enzyme-linked immunosorbent assay for diagnosis and follow-up of indian visceral leishmaniasis patients. Diagn Microbiol Infect Dis. 2004 Sep; 50(1):15-24. PMID: 15380274.
      View in: PubMed
    247. Gourbal B, Sonuc N, Bhattacharjee H, Legare D, Sundar S, Ouellette M, Rosen BP, Mukhopadhyay R. Drug uptake and modulation of drug resistance in Leishmania by an aquaglyceroporin. J Biol Chem. 2004 Jul 23; 279(30):31010-7. PMID: 15138256.
      View in: PubMed
    248. Chava AK, Chatterjee M, Sharma V, Sundar S, Mandal C. Variable degree of alternative complement pathway-mediated hemolysis in Indian visceral leishmaniasis induced by differential expression of 9-O-acetylated sialoglycans. J Infect Dis. 2004 Apr 01; 189(7):1257-64. PMID: 15031795.
      View in: PubMed
    249. Sundar S, Mehta H, Suresh AV, Singh SP, Rai M, Murray HW. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clin Infect Dis. 2004 Feb 01; 38(3):377-83. PMID: 14727208.
      View in: PubMed
    250. Bandyopadhyay S, Chatterjee M, Sundar S, Mandal C. Identification of 9-O-acetylated sialoglycans on peripheral blood mononuclear cells in Indian Visceral Leishmaniasis. Glycoconj J. 2004; 20(9):531-6. PMID: 15454691.
      View in: PubMed
    251. Bhattacharya SK, Jha TK, Sundar S, Thakur CP, Engel J, Sindermann H, Junge K, Karbwang J, Bryceson AD, Berman JD. Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India. Clin Infect Dis. 2004 Jan 15; 38(2):217-21. PMID: 14699453.
      View in: PubMed
    252. Sundar S, Jha TK, Thakur CP, Mishra M, Singh VP, Buffels R. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. Clin Infect Dis. 2003 Sep 15; 37(6):800-4. PMID: 12955641.
      View in: PubMed
    253. Sundar S. Diagnosis of kala-azar--an important stride. J Assoc Physicians India. 2003 Aug; 51:753-5. PMID: 14651132.
      View in: PubMed
    254. Singh N, Singh RT, Sundar S. Novel mechanism of drug resistance in kala azar field isolates. J Infect Dis. 2003 Aug 15; 188(4):600-7. PMID: 12898450.
      View in: PubMed
    255. Sundar S, Jha TK, Sindermann H, Junge K, Bachmann P, Berman J. Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis. Pediatr Infect Dis J. 2003 May; 22(5):434-8. PMID: 12792385.
      View in: PubMed
    256. Davies CR, Kaye P, Croft SL, Sundar S. Leishmaniasis: new approaches to disease control. BMJ. 2003 Feb 15; 326(7385):377-82. PMID: 12586674.
      View in: PubMed
    257. Sundar S, Benjamin B. Diagnosis and treatment of Indian visceral leishmaniasis. J Assoc Physicians India. 2003 Feb; 51:195-201. PMID: 12725267.
      View in: PubMed
    258. Chava AK, Chatterjee M, Sundar S, Mandal C. Development of an assay for quantification of linkage-specific O-acetylated sialoglycans on erythrocytes; its application in Indian visceral leishmaniasis. J Immunol Methods. 2002 Dec 01; 270(1):1-10. PMID: 12379333.
      View in: PubMed
    259. Sundar S, Rai M. Advances in the treatment of leishmaniasis. Curr Opin Infect Dis. 2002 Dec; 15(6):593-8. PMID: 12821836.
      View in: PubMed
    260. Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med. 2002 Nov 28; 347(22):1739-46. PMID: 12456849.
      View in: PubMed
    261. Eidsmo L, Wolday D, Berhe N, Sabri F, Satti I, El Hassan AM, Sundar S, Chiodi F, Akuffo H. Alteration of Fas and Fas ligand expression during human visceral leishmaniasis. Clin Exp Immunol. 2002 Nov; 130(2):307-13. PMID: 12390320.
      View in: PubMed
    262. Kumar P, Pai K, Pandey HP, Sundar S. NADH-oxidase, NADPH-oxidase and myeloperoxidase activity of visceral leishmaniasis patients. J Med Microbiol. 2002 Oct; 51(10):832-6. PMID: 12435061.
      View in: PubMed
    263. Kumar P, Pai K, Tripathi K, Pandey HP, Sundar S. Immunoblot analysis of the humoral immune response to Leishmania donovani polypeptides in cases of human visceral leishmaniasis: its usefulness in prognosis. Clin Diagn Lab Immunol. 2002 Sep; 9(5):1119-23. PMID: 12204969.
      View in: PubMed
    264. Sundar S, Rai M. Laboratory diagnosis of visceral leishmaniasis. Clin Diagn Lab Immunol. 2002 Sep; 9(5):951-8. PMID: 12204943.
      View in: PubMed
    265. Guerin PJ, Olliaro P, Sundar S, Boelaert M, Croft SL, Desjeux P, Wasunna MK, Bryceson AD. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis. 2002 Aug; 2(8):494-501. PMID: 12150849.
      View in: PubMed
    266. Sundar S, Sahu M, Mehta H, Gupta A, Kohli U, Rai M, Berman JD, Murray HW. Noninvasive management of Indian visceral leishmaniasis: clinical application of diagnosis by K39 antigen strip testing at a kala-azar referral unit. Clin Infect Dis. 2002 Sep 01; 35(5):581-6. PMID: 12173133.
      View in: PubMed
    267. Sundar S, Pai K, Sahu M, Kumar V, Murray HW. Immunochromatographic strip-test detection of anti-K39 antibody in Indian visceral leishmaniasis. Ann Trop Med Parasitol. 2002 Jan; 96(1):19-23. PMID: 11989529.
      View in: PubMed
    268. Sundar S, Agrawal G, Rai M, Makharia MK, Murray HW. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. BMJ. 2001 Aug 25; 323(7310):419-22. PMID: 11520836.
      View in: PubMed
    269. Sundar S, Gupta LB, Rastogi V, Agrawal G, Murray HW. Short-course, cost-effective treatment with amphotericin B-fat emulsion cures visceral leishmaniasis. Trans R Soc Trop Med Hyg. 2000 Mar-Apr; 94(2):200-4. PMID: 10897369.
      View in: PubMed
    270. Sundar S, Gupta LB, Makharia MK, Singh MK, Voss A, Rosenkaimer F, Engel J, Murray HW. Oral treatment of visceral leishmaniasis with miltefosine. Ann Trop Med Parasitol. 1999 Sep; 93(6):589-97. PMID: 10707104.
      View in: PubMed
    271. Sundar SK, Bergeron J, Menezes J. Purified plasminogen activating factor produced by malignant lymphoid cells abrogates lymphocyte cytotoxicity. Clin Exp Immunol. 1984 Jun; 56(3):701-8. PMID: 6430612.
      View in: PubMed
    Sundar's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description